Latest News

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

CANN marks 30th anniversary with expanded partnerships and cross-condition advocacy evolution.

Lupus Colorado partnership with CANN demonstrates how disease-specific and multi-condition advocates amplify healthcare policy impact.

2025 healthcare crises result from policy choices as ACA subsidies expire, HIV care deteriorates, and state pricing experiments proliferate.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

RFK Jr's budget testimony reveals plans to restructure HHS agencies and shift funding away from infectious disease prevention.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Elimination of health equity research funding undermines evidence base for addressing healthcare disparities and structural inequalities.

Pragmatic approach to healthcare policy reform requires accepting incremental progress while maintaining advocacy commitment.

Reflection on advocacy values and health equity commitment during political transitions.

Healthcare policy opportunities and threats during lame duck congressional session.

Bipartisan HCV elimination legislation analysis and critical legislative window.

Partisan political battles threaten essential public health programs and HIV funding.

Federal policy failures on copay accumulator programs restrict patient assistance benefits.